Cavapro 75 mg (Tablet)

Unit Price: ৳ 6.00 (3 x 10: ৳ 180.00)
Strip Price: ৳ 60.00

Medicine Details

Indications

  • Treatment of essential hypertension
  • Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus

Pharmacology

  • Angiotensin II receptor antagonist
  • Blocks vasoconstricting effects of angiotensin II
  • Blocks aldosterone-secreting effects by binding to AT1 receptors

Dosage & Administration

  • Usual recommended initial dose: Irbesartan 150 mg once daily
  • Maintenance dose: Irbesartan 150 mg once daily, with or without food
  • Better 24 hour blood pressure control with 150 mg than 75 mg
  • Consider initiation with Irbesartan 75 mg in haemodialysed patients and elderly over 75 years
  • Dose can be increased to Irbesartan 300 mg if insufficiently controlled with 150 mg

Interaction

  • Risk of hypotension when initiating therapy with diuretics and other antihypertensive agents
  • Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium not recommended
  • Potential reversible increases in serum lithium concentrations and toxicity with concomitant administration of lithium
  • Attenuation of antihypertensive effect when administered with non-steroidal anti-inflammatory drugs

Contraindications

  • Concomitant use with aliskiren in patients with diabetes and renal impairment (GFR <60 ml/min)
  • Pregnancy

Side Effects

  • Diarrhoea
  • Fatigue
  • Dyspepsia or heartburn
  • Dizziness
  • Orthostatic hypotension
  • Nausea
  • Vomiting
  • Musculoskeletal pain
  • Thrombocytopaenia
  • Hyperkalaemia
  • Elevated serum creatinine

Pregnancy & Lactation

  • Contraindicated in second and third trimesters of pregnancy
  • Avoid use during first trimester of pregnancy
  • Contraindicated during lactation
  • Not known whether excreted in human milk

Precautions & Warnings

  • Patients with unilateral or bilateral renal artery stenosis
  • Patients with depletion of intravascular volume
  • Patients with aortic or mitral stenosis
  • Patients with obstructive hypertrophic cardiomyopathy
  • Patients with renal impairment
  • Patients with hepatic impairment
  • Close monitoring of serum potassium in patients at risk

Use in Special Populations

  • No dosage adjustment necessary in patients with impaired renal function
  • Lower starting dose in patients undergoing haemodialysis
  • No dosage adjustment necessary in patients with mild to moderate hepatic impairment
  • Effects on renal and cardiovascular events not uniform across all subgroups in patients with advanced renal disease
  • Close monitoring of serum potassium in patients at risk
  • Special caution in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy
  • Not recommended for patients with primary aldosteronism
  • Association with acute hypotension in patients whose vascular tone and renal function depend predominantly on the renin-angiotensin-aldosterone system

Overdose Effects

  • No toxicity observed in adults exposed to doses of up to 900 mg/day for 8 weeks
  • Expected manifestations of overdosage: hypotension, tachycardia, bradycardia
  • No specific information available on treatment of overdosage with Cavapro
  • Symptomatic and supportive treatment suggested
  • Activated charcoal may be useful in treatment of overdosage
  • Not removed by haemodialysis

Therapeutic Class

  • Angiotensin-II receptor blocker

Storage Conditions

  • Store in a cool and dry place
  • Protected from light

Related Brands